Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility

Steven R Goldring

In recent decades there has been a dramatic change in the treatment approaches for management of rheumatoid arthritis (RA). The introduction of methotrexate and the subsequent development of the biological agents that target tumour necrosis factor (TNF) and/or immune cell activation pathways have dramatically improved patient outcomes. Nevertheless, as additional information becomes available from prospective studies of patients receiving these therapies, there is evidence that a significant number of individuals continue to experience progressive joint damage and functional impairment. Based on these observations, there is a need to develop validated assessment tools for identifying patients who are at risk for a poor prognosis and to target this population for more aggressive and/or specific therapies to prevent eventual joint damage. In this and a recent issue of the *Annals of Rheumatic Diseases*, two independent groups of investigators have utilized the techniques of bone mineral density (BMD) and radiographic analysis to assess bone loss in patients with early RA and to validate the changes in BMD as a predictor of subsequent joint damage.8

Both of the studies have exploited the evidence that the RA inflammatory process produces adverse effects on both local articular as well as systemic bone remodelling. The skeletal changes can be segregated into distinct patterns on the basis of anatomic site and distribution. These include focal marginal joint erosions (the radiographic hallmark of RA), subchondral bone erosions, periarticular osteoporosis and systemic osteoporosis. These skeletal changes are associated with net bone loss and in all instances are reflective of an imbalance in the activities of the cells that mediate bone resorption and formation.

In the work by Hoff et al (see page 324),10 the investigators used digital x-ray radiography (DXR) to assess hand BMD in a population of patients with early RA. Conventional hand radiographs were used for both the radiographic scoring and for BMD measurement. The BMD assessment was performed on the cortical bone in the narrowest region of the second through the fourth metacarpals. The BMD results were then correlated with the development of radiographic joint damage over the subsequent 10 years employing the van Heijde modification of the Sharp method. They observed that patients with hand BMD loss at 1 year had significantly greater joint damage compared to patients without BMD loss. Importantly, they showed that the hand BMD loss was an independent predictor of subsequent joint damage and that the predictive power was comparable to the established biomarkers, anti-cyclic citrullinated peptide (CCP) and C-reactive protein (CRP). Their findings confirmed the results of previous longitudinal studies.11

Multiple lines of evidence indicate that bone loss at both the metacarpal and joint margins reflect an imbalance in bone remodelling and that the reparative process is mediated via osteoclasts. These conclusions are based on histological observations of the bone resorption sites in periarticular bone and at the joint margins in patients with RA that confirm the presence of cells expressing definitive features of osteoclasts. More definitive evidence implicating osteoclasts in the pathogenesis of focal joint erosions comes from studies in knock-out mice with induced forms of inflammatory arthritis in which joint erosions fail to develop in the absence of osteoclasts. These results strongly implicate osteoclasts as the cell type responsible for the reparative process at both sites. However, the observation that the loss of cortical bone density precedes the development of joint erosions, suggests that the imbalance in local bone remodelling at these sites may involve two distinct pathophysiological mechanisms. With respect to the pathogenesis of marginal erosions, the findings implicate a direct effect of the synovial pannus, which produces a plethora of potent osteoclast-inducing factors and has been shown to contain abundant osteoclast precursors. In addition, recent studies by Diarra et al demonstrate that the RA synovium is a source of dickkopf-1 (DKK-1), an inhibitor of bone formation that mediates its effects by inactivating the wingless (Wnt)-signalling pathway. The suppression of bone formation and increased resorptive activity likely account for the rapid rate of focal bone loss at the pannus–bone interface.

In contrast, the loss of cortical bone at the metacarpal sites is remote from the synovial and subchondral marrow inflammation and implicates an alternate process that could reflect the adverse effects of reduced mechanical loading and relative joint immobilisation. These changes would be reflective of the property of bone to adapt its structural organisation in response to mechanical forces via remodelling according to Wolff’s hypothesis that states that the distribution and material properties of bone are determined by the magnitude and direction of applied load. An alternate possibility is that cytokines released from the synovium and/or bone marrow could act via a local gradient effect or via systemic delivery to increase osteoclast-mediated bone loss at the metacarpal sites. This mechanism has been suggested to explain the adverse effects of synovial inflammation on generalised skeletal remodelling. Of interest, in the Hoff study a subset of patients without hand BMD loss assessed by DXR experienced significant progressive marginal bone erosions. The disassociation between bone changes at the two sites provides additional indirect evidence suggesting that the pathogenic mechanisms responsible for the deregulated bone remodelling at the joint margins and periarticular location differs.

The studies by Guler-Yuksel et al’ provide further evidence linking changes in hand BMD measured by DXR with progression of erosive joint damage. As in the Hoff study, progression in bone erosions was independently associated with BMD loss. In addition to assessment of BMD and hand erosion scores, the authors also explored the relationship of skeletal changes at these sites with associated alterations in generalised skeletal BMD in the hip and spine measured by
dual energy X-ray absorptiometry (DEXA). Furthermore, they evaluated the effects of treatment interventions on the bone parameters by conducting their skeletal site evaluation in a cohort of patients enrolled in the BeSt (for “Behandel Strategieen”, in English “treatment strategies”) study.\textsuperscript{30,31} Patients in the BeSt study were randomised to one of four treatment categories: sequential monotherapy, step up combination therapy, initial combination therapy with tapered high-dose prednisone, or combination therapy with infliximab.

The authors observed that there was BMD loss at all locations in all treatment groups, although combination therapy with prednisone and infliximab was associated with less hand BMD loss compared to the other groups. There were several additional observations of interest. Across the treatment groups there was greater BMD loss in the hands than the hip or spine, and the loss of BMD in the hands preceded the changes in hip and spine. Their findings confirm earlier observations\textsuperscript{32,33} indicating a similar temporal relationship and suggest that differential pathogenic processes are involved in deregulated bone remodelling and bone loss systemically and in the hand.

The levels of multiple cytokines with osteoclast-inducing activity, including receptor activator of nuclear factor (NF)κB ligand (RANKL) (an essential molecule that is required for osteoclast formation and activity) are elevated in the sera of patients with RA. The increased systemic bone loss in RA has been attributed to the adverse effects of RANKL and additional pro-osteoclastogenic cytokines that are released into the circulation from sites of synovial inflammation and act in a manner similar to endocrine hormones to modulate systemic bone remodelling. Studies by Geusens et al\textsuperscript{34} support this speculation. They observed that the ratio of circulating RANKL and its inhibitor osteoprotegerin (OPG) predicted subsequent bone destruction in a cohort of patients with early RA. A similar endocrine-like mechanism also could contribute to impaired systemic bone formation. As discussed previously, Diarra et al\textsuperscript{37} noted that patients with RA had elevated serum levels of DKK-1. Importantly, they observed that the levels of this potent inhibitor of bone formation correlated with disease activity. Both the periaricular bone and general skeleton would be subject to the influence of synovial-derived cytokines that could increase osteoclast-mediated bone resorption and suppress bone formation. As discussed earlier, the microenvironment in the metacarpal region likely is influenced by additional local factors that include reduced loading or adjacent inflammatory processes. These factors and influences would not be present throughout the skeleton. The differential pattern of bone loss in the hand and generalised skeleton need to be interpreted with some caution since, as the authors point out, both the sensitivity and bone tissue specificity of the two techniques differ.

Guler-Yuksel et al\textsuperscript{36} also observed that bisphosphonates protected only against generalised BMD loss in the hip and spine and had no significant effect on bone erosions or BMD in the hands. These findings confirm the observations of earlier studies indicating differential effects of bisphosphonates on focal erosions and systemic bone remodelling.\textsuperscript{38} In a recent study Jarrett et al\textsuperscript{39} demonstrated a beneficial effect of bisphosphonates in a series of patients with early RA; however, the effects were limited and large and repeated dosing was required.\textsuperscript{40} The high turnover of osteoclast generation and activity could partially explain the failure of bisphosphonates to effectively inhibit focal bone resorption. Alternatively, these agents may not concentrate adequately at the resorption sites, and more direct targeting of osteoclasts differentiation and activation may be necessary, as has been shown recently in preliminary trials with a humanised monoclonal antibody to RANKL in patients with early RA.\textsuperscript{41}

The two above-mentioned manuscripts published in this journal provide further evidence of the association between periarticular bone loss and focal joint erosions. The pattern of bone loss provides insights into the underlying pathogenic mechanisms responsible for the deregulated bone remodelling and importantly suggests the potential utility of this diagnostic approach for predicting the natural history of RA joint damage and implementation of treatment approaches.\textsuperscript{46}

**Funding:** This work was supported in part by National Institute of Health Grant NIHMS R01 AR45472 and American College of Rheumatology Research and Education Foundation (ACRF-REF) Within Our Reach: Finding a Cure for Rheumatoid Arthritis.

**Competing interests:** None.

Accepted 16 November 2008


doi:10.1136/ard.2008.099408

**REFERENCES**


Landewe R, van der Heijde D, Klarenberg L, van Vollenhoven R, Faculty of rheumatology and association with disease activity. Both the study were randomised to one of four treatment categories: sequential monotherapy, step up combination therapy, initial combination therapy with tapered high-dose prednisone, or combination therapy with infliximab.

The authors observed that there was BMD loss at all locations in all treatment groups, although combination therapy with prednisone and infliximab was associated with less hand BMD loss compared to the other groups. There were several additional observations of interest. Across the treatment groups there was greater BMD loss in the hands than the hip or spine, and the loss of BMD in the hands preceded the changes in hip and spine. Their findings confirm earlier observations\textsuperscript{32,33} indicating a similar temporal relationship and suggest that differential pathogenic processes are involved in deregulated bone remodelling and bone loss systemically and in the hand.

The levels of multiple cytokines with osteoclast-inducing activity, including receptor activator of nuclear factor (NF)κB ligand (RANKL) (an essential molecule that is required for osteoclast formation and activity) are elevated in the sera of patients with RA. The increased systemic bone loss in RA has been attributed to the adverse effects of RANKL and additional pro-osteoclastogenic cytokines that are released into the circulation from sites of synovial inflammation and act in a manner similar to endocrine hormones to modulate systemic bone remodelling. Studies by Geusens et al\textsuperscript{34} support this speculation. They observed that the ratio of circulating RANKL and its inhibitor osteoprotegerin (OPG) predicted subsequent bone destruction in a cohort of patients with early RA. A similar endocrine-like mechanism also could contribute to impaired systemic bone formation. As discussed previously, Diarra et al\textsuperscript{37} noted that patients with RA had elevated serum levels of DKK-1. Importantly, they observed that the levels of this potent inhibitor of bone formation correlated with disease activity. Both the periaricular bone and general skeleton would be subject to the influence of synovial-derived cytokines that could increase osteoclast-mediated bone resorption and suppress bone formation. As


Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility
Steven R Goldring

Ann Rheum Dis 2009 68: 297-299
doi: 10.1136/ard.2008.099408

Updated information and services can be found at:
http://ard.bmj.com/content/68/3/297

These include:

References
This article cites 37 articles, 8 of which you can access for free at:
http://ard.bmj.com/content/68/3/297#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/68/6/1080.3.full.pdf

Topic Collections
Articles on similar topics can be found in the following collections
- Calcium and bone (725)
- Musculoskeletal syndromes (4951)
- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Osteoporosis (137)
- Rheumatoid arthritis (3258)
- Clinical diagnostic tests (1282)
- Epidemiology (1367)
- Radiology (1113)
- Radiology (diagnostics) (750)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Corrections

doi:10.1136/ard.2007.085050.corr1


An author name was incorrect in the an article published in February 2009 (G Moroni, A Radice, G Giammarresi, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. *Ann Rheum Dis* 2009; 68:234–7). The seventh author’s name should have been given as M Li Vecchi, not M L Vecchi as given in the article.

